

Dependent claims 66, 72-77

65: Independent method of suppressing autoimmune  
disease claim (p. 44)

Dependent claims 67, 78-82

NEW CLAIMS:


68: composition (p. 52)

69: method of producing (p. 56)

70: composition (p. 63)

71: composition (p. 66)

42. (once amended) A compound of formula (I) and pharmaceutically acceptable salts of formula (I)



(I)

wherein:

$R^1$  is selected from the group consisting of hydrogen, halogen, cyano,  $C_1$ - $C_6$ -alkyl, trifluoromethyl,  $C_3$ - $C_8$ -cycloalkyl,  $C_1$ - $C_4$ -hydroxyalkyl, hydroxy,  $C_1$ - $C_4$ -alkoxy, benzyloxy,  $C_2$ - $C_4$ -alkanoyloxy,  $C_1$ - $C_4$ -alkylthio,  $C_2$ - $C_5$ -alkoxycarbonyl, aminocarbonyl,  $C_3$ - $C_9$ -dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy,  $NR^5R^6$ , and bridged  $R^1R^2$  wherein

$R^5$  is selected from the group consisting of hydrogen and  $C_1$ - $C_6$ -alkyl; and

$R^6$  is selected from the group consisting of hydrogen and  $C_1$ - $C_6$ -alkyl;

$R^2$  is selected from the group consisting of hydrogen, halogen,  $C_1$ - $C_6$ -alkyl, trifluoromethyl and hydroxy and bridged  $R^1R^2$ ;

wherein

bridged  $R^1R^2$  is where  $R^1R^2$  are adjacent and form a bridge which is selected from the group consisting of  $-(CH_2)_4-$ ,  $(CH=CH)_2$  and  $-CH_2O-CR^7R^8-O-$ ; wherein

$R^7$  is selected from the group consisting of hydrogen, and  $C_1-C_6$ -alkyl; and

$R^8$  is selected from the group consisting of hydrogen and  $C_1-C_6$ -alkyl;

$R^3$  is selected from the group consisting of hydrogen, halogen and  $C_1-C_6$ -alkyl;

$R^4$  is selected from the group consisting of hydrogen,  $C_1-C_6$ -alkyl,  $C_3-C_6$ -alkenyl, hydroxy,  $C_1-C_6$ -alkoxy and benzyloxy;

$k$  is 0 or 1,

$A$  is selected from the group consisting of  $C_2-C_6$ -alkenylene, .

a substituted  $C_2-C_6$ -alkenylene which is substituted one to three-fold by  $C_1-C_3$ -alkyl, hydroxy, fluorine, cyano, or phenyl,  $C_4-C_6$ -alkadienylene,

a substituted  $C_4-C_6$ -alkadienylene which is substituted once or twice by  $C_1-C_3$ -alkyl, fluorine, cyano, or phenyl, 1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted by  $C_1-C_3$ -alkyl, fluorine, or cyano, and ethynylene;

$D$  is selected from the group consisting of

$C_1-C_{10}$ -alkylene,

a substituted  $C_1-C_{10}$ -alkylene which is substituted once or twice by  $C_1-C_3$ -alkyl or hydroxy,

$C_2-C_{10}$ -alkenylene,

a substituted  $C_2-C_{10}$ -alkenylene which is substituted once or twice by  $C_1-C_3$ -alkyl or hydroxy,

a substituted  $C_2-C_{10}$ -alkenylene which is substituted once or twice by  $C_1-C_3$ -alkyl or hydroxy, wherein the double bond is to E,


$C_3-C_{10}$ -alkynylene,

a substituted  $C_3-C_{10}$ -alkynylene which is substituted once or twice by  $C_1-C_3$ -alkyl or hydroxy,

an isosterically replaced  $C_1$  to  $C_{10}$  group selected from the group consisting of  $C_1-C_{10}$ -alkylene,  $C_2-C_{10}$ -alkenylene and  $C_3-C_{10}$ -alkynylene, the isosterically replaced  $C_1$  to  $C_{10}$  group having methylene units and one to three of the methylene units are isosterically replaced by O, S,  $NR^9$ , CO, SO or  $SO_2$ ; wherein

$R^9$  is selected from the group consisting of hydrogen,  $C_1-C_3$ -alkyl,  $C_2-C_6$ -acyl and methanesulfonyl;

E is



wherein  $n$  and  $p$  are, independent of each other, 0, 1, 2, or 3, wherein  $n + p \leq 3$ ,

$R^{10}$  is selected from the group consisting of hydrogen,  $C_1$ -

C<sub>3</sub>-alkyl, hydroxy, hydroxymethyl, carboxy and C<sub>2</sub>-C<sub>7</sub>-alkoxycarbonyl;

D1  
cont  
R<sup>11</sup> is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E;

G is selected from the group consisting of hydrogen, G1, G2, G3, G4 and G5; wherein

C1  
G1 is  $-(CH_2)_r-(C(R^{13}R^{14})_s-R^{12})$   
wherein

r is 0, 1 or 2, and

s is 0 or 1,

R<sup>12</sup> is selected from the group consisting of hydrogen,

C<sub>1</sub>-C<sub>6</sub>-alkyl,

C<sub>3</sub>-C<sub>6</sub>-alkenyl,

C<sub>3</sub>-C<sub>6</sub>-alkinyl,

C<sub>3</sub>-C<sub>8</sub>-cycloalkyl,

benzyl,

phenyl,

monocyclic aromatic five- and six-membered heterocycles which heterocycles contain one to three hetero-atoms selected from the group consisting of N, S and O, which heterocycles are either bound directly to or over a methylene group,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and aromatic ring being bonded with a bond which is either over an

D'  
cont

aromatic or a hydrogenated ring and either directly or over a methylene group, and

CI

a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms are selected from N, S and O and the carbocyclic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring, and either directly or over a methylene group;

R<sup>13</sup> has the same meaning as R<sup>12</sup>, but is selected independently thereof,

R<sup>14</sup> is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl,



monocyclic aromatic five- and six-membered heterocycles which contain one to three hetero-atoms selected from the group consisting of N, S and O and are bound either directly or over a methylene group,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and the aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and


a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, which heterocycles contain one to three ring atoms are selected from N, S and O and the heterocyclic ring and aromatic ring being bonded with

a bond which is over an aromatic or a hydrogenated ring and either directly or over a methylene group;

G2 is selected from the group consisting of



and



wherein  $\text{R}^{12}$  and  $\text{R}^{14}$  have the above meaning, and Q is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of

saturated and unsaturated monocyclic, four- to eight-membered heterocycles,

saturated and unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,


saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, and

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside

from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

G3 is  $-\text{SO}_2-(\text{CH}_2)_r-\text{R}^{13}$ ,

G4 is



wherein

$\text{Ar}^1$  is selected from the group consisting of phenyl, pyridyl and naphthyl; and

$\text{Ar}^2$  is selected from the group consisting of phenyl, pyridyl and naphthyl;

G5 is  $-\text{COR}^{15}$ ,

wherein

$\text{R}^{15}$  is selected from the group consisting of trifluoromethyl,  $\text{C}_1\text{-C}_6\text{-alkoxy}$ ,  $\text{C}_3\text{-C}_6\text{-alkenyloxy}$  and benzyloxy; and

wherein aromatic rings in  $\text{R}^1$ ,  $\text{R}^4$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ , Q,  $\text{Ar}^1$  and  $\text{Ar}^2$  are unsubstituted or substituted, the substituted rings in  $\text{R}^1$ ,  $\text{R}^4$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ , Q,  $\text{Ar}^1$  and  $\text{Ar}^2$  having one to three substituents which are independently selected from the group consisting of halogen, cyano,  $\text{C}_1\text{-C}_6\text{-alkyl}$ , trifluoromethyl,  $\text{C}_3\text{-C}_8\text{-cycloalkyl}$ , phenyl, benzyl, hydroxy,  $\text{C}_1\text{-C}_6\text{-alkoxy}$ , and a



B1  
cont

substituted C<sub>1</sub>-C<sub>6</sub>-alkoxy which is entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C<sub>1</sub>-C<sub>6</sub>-alkylthio, carboxy, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C<sub>1</sub>-C<sub>6</sub>-alkylamino, and di-(C<sub>1</sub>-C<sub>6</sub>-alkyl)-amino, wherein two adjacent groups of an aromatic ring in the substituted C<sub>1</sub>-C<sub>6</sub> alkoxy may form an additional ring over a methylenedioxy bridge, wherein general formula (I) does not include (E)-3-(3-pyridyl)-N-[2-(1-benzylpiperidin-4-yl)ethyl]-2-propenamide.

01

43. (once amended) A compound according to claim 42, wherein:

R<sup>1</sup> is selected from the group consisting of hydrogen, halogen, cyano, methyl, trifluoromethyl, hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, ethylthio, methoxycarbonyl, tert-butoxycarbonyl, aminocarbonyl, carboxy, and phenoxy,

R<sup>2</sup> is selected from the group consisting of hydrogen, halogen, trifluoromethyl and hydroxy,

R<sup>3</sup> is hydrogen or halogen,

R<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy and C<sub>1</sub>-C<sub>3</sub>-alkoxy,

k is 0 or 1,

A is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>6</sub>-alkenylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy or fluorine,

*D1*  
*cont*

a C<sub>4</sub>-C<sub>6</sub>-alkadienylene,  
a substituted C<sub>4</sub>-C<sub>6</sub>-alkadienylene which is substituted  
by C<sub>1</sub>-C<sub>3</sub>-alkyl or by 1 or 2 fluorine atoms,  
1,3,5-hexatrienylene, and  
a substituted 1,3,5-hexatrienylene which is substituted  
by fluorine,

*C1*

D is selected from the group consisting of C<sub>1</sub>-C<sub>8</sub>-  
alkylene,

a substituted C<sub>1</sub>-C<sub>8</sub>-alkylene which is substituted once or  
twice by methyl or hydroxy,

C<sub>2</sub>-C<sub>8</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>8</sub>-alkenylene which is substituted once  
or twice by methyl or hydroxy,


an E double bonded substituted C<sub>2</sub>-C<sub>8</sub>-alkenylene which has  
a double bond to ring E,

C<sub>3</sub>-C<sub>8</sub>-alkynylene,

a substituted C<sub>3</sub>-C<sub>8</sub>-alkynylene which is substituted once  
or twice by methyl or hydroxy, and

an isosterically replaced C1 to C8 group selected from  
the group consisting of C<sub>1</sub>-C<sub>8</sub>-alkylene, C<sub>2</sub>-C<sub>8</sub>-alkenylene and  
C<sub>3</sub>-C<sub>8</sub>-alkynylene, the isosterically replaced C1 to C8 group  
having methylene units and one to three methylene units are  
isosterically replaced by O, S, NH, N(CH<sub>3</sub>), N(COCH<sub>3</sub>),  
N(SO<sub>2</sub>CH<sub>3</sub>), CO, SO or SO<sub>2</sub>,

E is



*C1*

wherein **n** and **p** are, independent of each other, 0, 1, 2, or 3, wherein  $n + p \leq 3$ ,

**R<sup>10</sup>** is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy, hydroxymethyl, carboxy and C<sub>2</sub>-C<sub>7</sub>-alkoxycarbonyl;

**R<sup>11</sup>** is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E;

**G** is selected from the group consisting of hydrogen, **G1**, **G2**, **G3**, **G4** and **G5**; wherein

**G1** is  $-(CH_2)_r-(CR^{13}R^{14})_s-R^{12}$   
wherein

**r** is 0, 1 or 2, and

**s** is 0 or 1,

**R<sup>12</sup>** is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, benzyl, phenyl, benzocyclobutyl, indanyl, indenyl, oxoindanyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, oxotetrahydronaphthyl, biphenylenyl, fluorenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, phenanthryl, dihydrophenanthryl, oxodihydrophenanthryl,

*Df*  
*ant*  
*Cl*



dibenzocycloheptenyl, oxodibenzocycloheptenyl,  
dihydrodibenzocycloheptenyl, oxodihydrodibenzocycloheptenyl,  
dihydrodibenzocyclooctenyl, tetrahydrodibenzocyclooctenyl and  
oxotetrahydrodibenzocyclooctenyl, bound directly or over a  
methylene group, furyl, thienyl, pyrrolyl, oxazolyl,  
isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl,  
oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl,  
pyridazinyl, pyrimidinyl, triazinyl, imidazothiazolyl,  
benzofuryl, dihydrobenzofuryl, benzothienyl,  
dihydrobenzothienyl, indolyl, indolinyl, oxoindolinyl,  
dioxoindolinyl, benzoxazolyl, oxobenzoxazolyl,  
benzisoxazolyl, oxobenzisoxazolyl, benzothiazolyl,  
oxobenzthiazolyl, benzoisothiazolyl, oxobenzoisothiazolyl,  
benzimidazolyl, oxobenzimidazolyl, indazolyl,  
oxoindazolyl, benzofurazanyl, benzothiadiaazolyl,  
benzotriazolyl, oxazolopyridyl, oxodihydrooxazolopyridyl,  
thiazolopyridyl, oxodihydrothiazolopyridyl,  
isothiazolopyridyl, imidazopyridyl, oxodihydroimidazopyridyl,  
pyrazolopyridyl, oxodihydropyrazolopyridyl, thienopyrimidinyl,  
chromanyl, chromanonyl, benzopyranyl, chromonyl, quinolyl,  
isoquinolyl, dihydroquinolyl, oxodihydroquinolyl,  
tetrahydroquinolyl, oxotetrahydroquinolyl, benzodioxanyl,  
quinoxalyl, quinazolinyl, naphthyridinyl, carbazolyl,  
tetrahydrocarbazolyl, oxotetrahydrocarbazolyl, pyridoindolyl,  
acridinyl, oxodihydroacridinyl, phenothiazinyl,  
dihydrodibenzoxepinyl, oxodihydrodibenzoxepinyl,  
benzocycloheptathienyl, oxobenzocycloheptathienyl,  
dihydrothienobenzothiepinyl, oxodihydrothienobenzothiepinyl,  
dihydrodibenzothiepinyl, oxodihydrodibenzothiepinyl,  
octahydrodibenzothiepinyl, dihydrodibenzazepinyl,  
oxodihydrodibenzazepinyl, octahydrodibenzazepinyl,  
benzocycloheptapyridyl, oxobenzocycloheptapyridyl,

9' cont  
 dihydropyridobenzodiazepinyl, dihydrodibenzoxazepinyl, dihydropyridobenzoxepinyl, dihydrodibenzothiazepinyl, oxodihydropyridobenzoxazepinyl, dihydrodibenzothiazepinyl, oxodihydrodibenzothiazepinyl, dihydropyridobenzothiazepinyl, and oxodihydropyridobenzothiazepinyl, bound directly or over a methylene group,


C'  
 $R^{13}$  has the same meaning as  $R^{12}$ , but is selected independently therefrom,

$R^{14}$  is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl, indanyl, indenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, benzofuryl, benzothienyl, indolyl, indolinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, chromanyl, quinolyl, and tetrahydroquinolyl, bound directly or over a methylene group,

G2 is selected from the group consisting of



and




wherein  $R^{12}$  and  $R^{14}$  have the above meaning, and Q is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of azetidine, pyrrolidine, piperidine, (1H)tetrahydropyridine, hexahydroazepine, (1H)tetrahydroazepine, octahydroazocine, pyrazolidine, piperazine, hexahydrodiazepine, morpholine, hexahydrooxazepine, thiomorpholine, thiomorpholine-1,1-dioxide, 5-aza-bicyclo[2.1.1]hexane, 2-aza-bicyclo[2.2.1]heptane, 7-aza-bicyclo[2.2.1]heptane, 2,5-diaza-bicyclo[2.2.1]heptane, 2-aza-bicyclo[2.2.2]octane, 8-aza-bicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, 9-azabicyclo[3.3.1]nonane, indoline, isoindoline, (1H)-dihydroquinoline, (1H)-tetrahydroquinoline, (2H)-tetrahydroisoquinoline, (1H)-tetrahydroquinoxaline, (4H)-dihydrobenzoxazine, (4H)-dihydrobenzothiazine, (1H)-tetrahydrobenzo[b]azepine, (1H)-tetrahydrobenzo[c]azepine, (1H)-tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine, (5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole, (10H)-dihydroacridine, 1,2,3,4-tetrahydroacridanone, (10H)-phenoxazine, (10H)-phenothiazine, (5H)-dibenzazepine, (5H)-dihydrodibenzazepine, (5H)-octahydrodibenzazepine, (5H)-dihydrodibenzodiazepine, (11H)-dihydrodibenzo[b,e]oxazepine, (11H)-dihydrodibenzo[b,e]thiazepine, (10H)-dihydrodibenzo[b,f]oxazepine, (10H)-

dihydrodibenzo[b,f]thiazepine, and  
(5H)-tetrahydrodibenzazocine,

G3 is  $-\text{SO}_2-(\text{CH}_2)_r-\text{R}^{12}$ ,

G4 is



wherein

$\text{Ar}^1$  and

$\text{Ar}^2$  are selected independently of each other from the  
group consisting of phenyl, pyridyl and naphthyl;

G5 is  $-\text{COR}^{15}$ ,

wherein

$\text{R}^{15}$  is selected from the group consisting of  
trifluoromethyl,  $\text{C}_1\text{-C}_6\text{-alkoxy}$ ,  $\text{C}_3\text{-C}_6\text{-alkenyloxy}$  and benzyloxy;  
and

wherein aromatic rings are substituted or unsubstituted  
independently of each other by  
one to three substituents which are independently selected  
from the group consisting of halogen, cyano,  $\text{C}_1\text{-C}_6\text{-alkyl}$ ,  
trifluoromethyl,  $\text{C}_3\text{-C}_6\text{-cycloalkyl}$ , phenyl, benzyl, hydroxy,  $\text{C}_1\text{-C}_6\text{-alkoxy}$ ,  
and a substituted  $\text{C}_1\text{-C}_6\text{-alkoxy}$  which is entirely or  
partially substituted by fluorine; benzyloxy, phenoxy,  
mercapto,  $\text{C}_1\text{-C}_6\text{-alkylthio}$ , carboxy,  $\text{C}_1\text{-C}_6\text{-alkoxycarbonyl}$ ;

benzyloxycarbonyl, nitro, amino, mono-C<sub>1</sub>-C<sub>6</sub>-alkylamino, and di-(C<sub>1</sub>-C<sub>6</sub>-alkyl)-amino, wherein two adjacent groups of an aromatic ring in the substituted C1-C6 alkoxy may form an additional ring over a methylenedioxy bridge.

D1  
Cont 44. (once amended) A compound according to claim 43 wherein:

C1 R<sup>1</sup> is selected from the group consisting of hydrogen, halogen, cyano, methyl, trifluoromethyl, hydroxy, methoxy and methoxycarbonyl,

R<sup>2</sup> is hydrogen or halogen,

R<sup>3</sup> is hydrogen,

R<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub>-alkyl and hydroxy,

k is 0 or 1,

A is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>6</sub>-alkenylene which is substituted once or twice by hydroxy or fluorine,

C<sub>4</sub>-C<sub>6</sub>-alkadienylene,

a substituted C<sub>4</sub>-C<sub>6</sub>-alkadienylene which is substituted by one or two fluorine atoms, and

1,3,5-hexatrienylene

D is selected from the group consisting of C<sub>2</sub>-C<sub>8</sub>-alkylene, a substituted C<sub>2</sub>-C<sub>8</sub>-alkylene which is substituted by



methyl or hydroxy


C<sub>2</sub>-C<sub>8</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>8</sub>-alkenylene which is substituted by methyl or hydroxy,

a substituted C<sub>2</sub>-C<sub>8</sub>-alkenylene which is substituted by methyl or hydroxy, wherein the double bond is to ring E,

an isosterically replaced C<sub>2</sub> to C<sub>8</sub> group selected from the group consisting of C<sub>2</sub>-C<sub>8</sub>-alkylene and C<sub>2</sub>-C<sub>8</sub>-alkenylene, the isosterically replaced C<sub>2</sub> to C<sub>8</sub> group having methylene units and one to three of the methylene units are isosterically replaced by O, NH, N(CH<sub>3</sub>), N(COCH<sub>3</sub>), N(SO<sub>2</sub>CH<sub>3</sub>) or CO,

E is






wherein **n** and **p** are, independent of each other, 0, 1, 2, or 3, wherein  $n + p \leq 3$ ,

**R<sup>10</sup>** is selected from the group consisting of hydrogen, methyl and hydroxyl,

**R<sup>11</sup>** is hydrogen or an oxo group adjacent to the nitrogen atom,

**G** is selected from the group consisting of hydrogen, C<sub>3</sub>-

C<sub>8</sub>-cycloalkyl, methoxycarbonyl, tert-butoxycarbonyl,  
benzyloxycarbonyl, trifluoroacetyl, diphenylphosphinoyl,



and



wherein

*r* is 0, 1 or 2,

*s* is 0 or 1,

*R*<sup>12</sup> is selected from the group consisting of hydrogen, methyl, benzyl, phenyl, indanyl, indenyl, oxoindanyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, oxotetrahydronaphthyl, flourenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, dibenzocycloheptenyl, and oxodibenzocycloheptenyl, dihydrodibenzocycloheptenyl, oxodihydrodibenzocycloheptenyl bound directly or over a methylene group, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl,

*D'*  
*Cont*

pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, imidazothiazolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, dihydrobenzothienyl, indolyl, indolinyl, oxoindolinyl, dioxoindolinyl, benzoxazolyl, oxobenzoxazolyl, benzisoxazolyl, oxobenzisoxazolyl, benzothiazolyl, oxobenzthiazolyl, benzoisothiazolyl, oxobenzoisothiazolyl, benzimidazolyl, oxobenzimidazolyl, benzofurazanyl, benzothiadiaazolyl, benzotriazolyl, oxazolopyridyl, oxodihydrooxazolopyridyl, thiazolopyridyl, oxodihydrothiazolopyridyl, isothiazolopyridyl, imidazopyridyl, oxodihydroimidazopyridyl, pyrazolopyridyl, thienopyrimidinyl, chromanyl, chromanonyl, benzopyranyl, chromonyl, quinolyl, isoquinolyl, dihydroquinolyl, oxodihydroquinolyl, tetrahydroquinolyl, oxotetrahydroquinolyl, benzodioxanyl, quinoxalyl, quinazolyl, naphthyridinyl, carbazolyl, tetrahydrocarbazolyl, oxotetrahydrocarbazolyl, pyridoindolyl, acridinyl, oxodihydroacridinyl, phenothiazinyl, dihydrodibenzoxepinyl, benzocycloheptathienyl, oxobenzocycloheptathienyl, dihydrothienobenzothiepinyl, oxodihydrothienobenzothiepinyl, dihydrodibenzothiepinyl, oxodihydrodibenzothiepinyl, dihydrodibenzazepinyl, oxodihydrodibenzazepinyl, octahydrodibenzazepinyl, benzocycloheptapyridyl, oxobenzocycloheptapyridyl, dihydropyridobenzoxepinyl, dihydrodibenzothiazepinyl, and oxodihydrodibenzothiazepinyl, bound directly or over a methylene group,

*C'*


R<sup>13</sup> is selected from the group consisting of hydrogen, methyl, benzyl and phenyl,

R<sup>14</sup> is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl, naphthyl, furyl, thienyl,

*9'*  
*Cont*

oxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, benzofuryl, benzothienyl, indolyl, indolinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, chromanlyl, quinolyl and tetrahydroquinolyl, bound directly or over a methylene group,

wherein in formula



*c'*

-NR<sup>12</sup>R<sup>14</sup> may be selected from the group consisting of pyrrolidine, piperidine, (1H)-tetrahydropyridine, hexahydroazepine, octahydroazocine, piperazine, hexahydrodiazepine, morpholine, hexahydrooxazepine, 2-azabicyclo[2.2.1]heptane, 7-azabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.1]heptane, 8-azabicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, indoline, isoindoline, (1H)-dihydroquinoline, (1H)-tetrahydroquinoline, (2H)-tetrahydroisoquinoline, (1H)-tetrahydroquinoxaline, (4H)-dihydrobenzoxazine, (4H)-dihydrobenzothiazine, (1H)-tetrahydrobenzo[b]azepine, (1H)-tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine, (5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol, (10H)-dihydroacridine, 1,2,3,4-tetrahydroacridanone, (5H)-dihydrodibenzazepine, (5H)-dihydrodibenzodiazepine, (11H)-dihydrodibenzo[b,e]oxazepine, (11H)-dihydrodibenzo[b,e]thiazepine, (10H)-dihydrodibenzo[b,f]oxazepine and (5H)-tetrahydrodibenzazocine,

wherein aromatic rings are substituted or unsubstituted independently of each other by one to three substituents independently selected from the group consisting of halogen,

01  
ant

cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, trifluoromethyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, phenyl, benzyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, and a substituted C<sub>1</sub>-C<sub>6</sub>-alkoxy entirely or partially substituted by fluorine; benzyloxy, phenoxy, mercapto, C<sub>1</sub>-C<sub>6</sub>-alkylthio, carboxy, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C<sub>1</sub>-C<sub>6</sub>-alkylamino, and di-(C<sub>1</sub>-C<sub>6</sub>-alkyl)-amino, wherein two adjacent groups of an aromatic ring in the substituted C<sub>1</sub>-C<sub>6</sub> alkoxy form an additional ring over a methylenedioxy bridge.

C1

45. (once amended) A compound according to claim 22, wherein

R<sup>1</sup> is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl and hydroxy,

R<sup>2</sup> and

R<sup>3</sup> are hydrogen,

R<sup>4</sup> is hydrogen or hydroxy,

k is 0 or 1,

A is selected from the group consisting of C<sub>2</sub>-C<sub>4</sub>-alkenylene,

1,3-butadienylene,

a C<sub>2</sub>-C<sub>4</sub>-alkenylene substituted by fluorine, and

a 1,3-butadienylene substituted by fluorine,

D is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub>-alkylene, C<sub>2</sub>-C<sub>6</sub>-alkenylene,




C<sub>2</sub>-C<sub>6</sub>-alkylene and C<sub>2</sub>-C<sub>6</sub>-alkenylene wherein the double

bond is to ring E, and


*D'*  
*cont* an isosterically replaced C2 to C6 group selected from the group consisting of C<sub>2</sub>-C<sub>6</sub>-alkylene and C<sub>2</sub>-C<sub>6</sub>-alkenylene, the isosterically replaced C2 to C6 group having a methylene unit which is isosterically replaced by O, NH, N(CH<sub>3</sub>) or CO, or an ethylene group which is isosterically replaced by NH-CO or CO-NH, or a propylene group which is isosterically replaced by NH-CO-O or O-CO-NH,

*C1* **E** is selected from the group consisting of piperidine, and a substituted piperidine wherein the heterocyclic ring is substituted by an oxo group adjacent to the nitrogen atom,

**G** is selected from the group consisting of hydrogen, tert-butoxycarbonyl, diphenylphosphinoyl,



and



wherein

*19'*  
*cont*  
 $r$  is 0 or 1,

$s$  is 0 or 1,


*cl*  
 $\text{R}^{12}$  is selected from the group consisting of hydrogen, methyl, benzyl, phenyl, indenyl, oxoindanyl, naphthyl, tetrahydronaphthyl, fluorenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, dibenzocycloheptenyl, and dihydrodibenzocycloheptenyl, bound directly or over a methylene group, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, imidazothiazolyl, benzofuryl, benzothenyl, indolyl, oxoindolinyl, dioxoindolinyl, benzoxazolyl, oxobenzoxazolyl, benzothiazolyl, oxobenzthiazolyl, benzimidazolyl, oxobenzimidazolyl, benzofurazanyl, benzotriazolyl, oxazolopyridyl, oxodihydrooxazolopyridyl, thiazolopyridyl, oxodihydrothiazolopyridyl, chromanyl, chromanonyl, benzopyranyl, chromonyl, quinolyl, isoquinolyl, oxodihydroquinolyl, tetrahydroquinolyl, oxotetrahydroquinolyl, benzodioxanyl, quinazolyl, acridinyl, oxodihydroacridinyl, phenothiazinyl, dihydrodibenzoxepinyl, benzocycloheptathienyl, dihydrothienobenzothiepinyl, dihydrodibenzothiepinyl, oxodihydrodibenzothiepinyl, dihydrodibenzazepinyl, oxodihydrodibenzazepinyl, octahydrodibenzazepinyl, benzocycloheptapyridyl, oxobenzocycloheptapyridyl, and

dihydrodibenzothiazepinyl, bound directly or over a methylene group,

*D1*  
*Cont*  
**R<sup>13</sup>** is selected from the group consisting of hydrogen, methyl, benzyl and phenyl,

*C1*  
**R<sup>14</sup>** is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl, naphthyl, furyl, thienyl, pyridyl, benzofuryl, benzothienyl, indolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, chromanyl, quinolyl and tetrahydroquinolyl, bound directly or over a methylene group,

wherein in the formula



(G2b)

**---NR<sup>12</sup>R<sup>14</sup>** may be selected from pyrrolidine, piperidine, hexahydroazepine, morpholine, 2,5-diazabicyclo[2.2.1]heptane, indoline, isoindoline, (1H)-dihydroquinoline, (1H)-tetrahydroquinoline, (2H)-tetrahydroisoquinoline, (1H)-tetrahydrobenzo[b]azepine, (1H)-tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine, (5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-tetrahydroacridanone, (5H)-dihydrodibenzazepine, (11H)-dihydrodibenzo[b,e]oxazepine and (11H)-dihydrodibenzo[b,e]thiazepine,

wherein aromatic rings are substituted or unsubstituted, independently of each other, by one to three substituents which are independently selected from the group consisting of halogen, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, trifluoromethyl, C<sub>3</sub>-C<sub>8</sub>-



*D1*  
*Cont*

cycloalkyl, phenyl, benzyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, a substituted C<sub>1</sub>-C<sub>6</sub>-alkoxy which is entirely or partially substituted by fluorine; benzyloxy, phenoxy, mercapto, C<sub>1</sub>-C<sub>6</sub>-alkylthio, carboxy, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C<sub>1</sub>-C<sub>6</sub>-alkylamino and di-(C<sub>1</sub>-C<sub>6</sub>-alkyl)-amino, wherein two adjacent groups on the aromatic ring or ring system may form an additional ring over a methylenedioxy bridge.

*C1*

46. (once amended) A compound according to claim 45, wherein:

- R<sup>1</sup>** is selected from the group consisting of hydrogen, fluorine, methyl, trifluoromethyl and hydroxy,
- R<sup>2</sup>** and
- R<sup>3</sup>** are hydrogen,
- R<sup>4</sup>** is hydrogen or hydroxy,
- k** is 0,
- A** is ethenylene or 1,3-butadienylene
- D** is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub>-alkylene, C<sub>2</sub>-C<sub>6</sub>-alkenylene, a C<sub>2</sub>-C<sub>6</sub>-alkylene wherein the double bond is to ring E, and a C<sub>2</sub>-C<sub>6</sub>-alkenylene wherein the double bond is to ring E,
- E** is selected from the group consisting of pyrrolidine, piperidine, hexahydroazepine and morpholine,
- G** is selected from the group consisting of benzyl, phenethyl, fluorenylmethyl, anthrylmethyl,

B'  
Cont

C1

diphenylmethyl, fluorenyl, dihydrodibenzocycloheptenyl, furylmethyl, thienylmethyl, thiazolylmethyl, pyridylmethyl, benzothienylmethyl, quinolylmethyl, phenylthienylmethyl, phenylpyridylmethyl, dihydrodibenzoxepinyl, dihydrodibenzothiepinyl, acetyl, pivaloyl, phenylacetyl, diphenylacetyl, diphenylpropionyl, naphthylacetyl, benzoyl, naphthoyl, anthrylcarbonyl, oxofluorenylcarbonyl, oxodihydroanthrylcarbonyl, dioxodihydroanthrylcarbonyl, furoyl, pyridylcarbonyl, chromonylcarbonyl, quinolylcarbonyl, naphthylaminocarbonyl, dibenzylaminocarbonyl, benzylphenylaminocarbonyl, diphenylaminocarbonyl, indolinyl-1-carbonyl, dihydrodibenzazepin-N-carbonyl, tetrahydroquinolinyl-N-carbonyl, tetrahydrobenzo[b]azepinyl-N-carbonyl, methanesulfonyl, phenylsulfonyl, p-toluenesulfonyl, naphthylsulfonyl, quinolinsulfonyl, and diphenylphosphinoyl,

wherein aromatic rings are substituted or unsubstituted independently of each other by one to three substituents which are independently selected from the group consisting of halogen, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, trifluoromethyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, phenyl, benzyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, entirely or partially substituted by fluorine; benzyloxy, phenoxy, mercapto, C<sub>1</sub>-C<sub>6</sub>-alkylthio, carboxy, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C<sub>1</sub>-C<sub>6</sub>-alkylamino and di-(C<sub>1</sub>-C<sub>6</sub>-alkyl)-amino, wherein two adjacent groups in the ring or ring system may form an additional ring over a methylenedioxy bridge.

47. (once amended) A compound according to claim 4,

which is selected from the group consisting of

1. N-[4-(1-methylsulfonylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,

2. N-[4-[1-(2-naphthylsulfonyl)-piperidin-4-yl]-butyl]-3-(pyridin-3-yl)-acrylamide,

3. N-[4-[1-(2-naphthylsulfonyl)-piperidin-4-yl]-butyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid amide,

4. N-[4-[1-(1-naphthylaminocarbonyl)-piperidin-4-yl]-butyl]-3-(pyridin-3-yl)-acrylamide,

5. N-[4-(1-diphenylaminocarbonyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,

6. N-[4-(1-diphenylaminocarbonyl-piperidin-4-yl)-butyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid amide,

7. N-[4-[1-(10,11-dihydrodibenzo[b,f]azepin-5-yl-carbonyl)-piperidin-4-yl]-butyl]-3-(pyridin-3-yl)-acrylamide, and

8. N-[4-(1-diphenylphosphinoyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide

or as a pharmaceutically acceptable acid addition salt thereof.

48. (once amended) A compound according to claim 42, which is selected from the group consisting of N-[4-(1-acetylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide,

N-[4-(1-diphenylacetyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide, N-{4-[1-(3,3-diphenylpropionyl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide, N-[4-(1-benzoylpiperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide, N-[4-(1-benzoylpiperidin-4-yl)-butyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid amide, and N-{4-[1-(9-oxo-9H-fluoren-4-yl-carbonyl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide, or as a pharmaceutically acceptable acid addition salt thereof.


49. (once amended) A compound according to claim 42, which is selected from the group consisting of N-{4-[1-(phenylpyridin-3-yl-methyl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide, N-{4-[1-(phenylpyridin-4-yl-methyl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide, N-{4-[1-(6,11-dihydrodibenzo[b,e]oxepin-11-yl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide and N-{4-[1-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)-piperidin-4-yl]-butyl}-3-(pyridin-3-yl)-acrylamide, or as a pharmaceutically acceptable acid addition salt thereof.

50. (once amended) A compound according to claim 42, which is selected from the group consisting of N-[7-(1-diphenylmethylpiperidin-4-yl)-heptyl]-3-(pyridin-3-yl)-acrylamide, N-[8-(1-diphenylmethylpiperidin-4-yl)-octyl]-3-(pyridin-3-yl)-acrylamide, N-[3-(1-diphenylmethylpiperidin-4-yloxy)-propyl]-3-(pyridin-3-yl)-acrylamide, and N-[3-(1-benzylpiperidin-4-yloxy)-propyl]-3-(pyridin-3-yl)-acrylamide or as a pharmaceutically acceptable acid addition salt thereof.

51. (once amended) A compound according to claim 42,

c1  
which is selected from the group consisting of N-[2-(1-diphenylmethylpiperidin-4-yl)-ethyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid amide, N-[4-(1-diphenylmethylpiperidin-4-yl)-butyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid amide, N-[5-(1-diphenylmethylpiperidin-4-yl)-pentyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid amide and N-[6-(1-diphenylmethylpiperidin-4-yl)-hexyl]-5-(pyridin-3-yl)-2,4-pentadienoic acid amide or as a pharmaceutically acceptable acid addition salt thereof.

56. (once amended) A pharmaceutical composition comprising one or more of the compounds according to formula (I) and pharmaceutically acceptable salts of formula (I)



wherein:

R<sup>1</sup> is selected from the group consisting of hydrogen, halogen, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, trifluoromethyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, C<sub>1</sub>-C<sub>4</sub>-hydroxyalkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, benzyloxy, C<sub>2</sub>-C<sub>4</sub>-alkanoyloxy, C<sub>1</sub>-C<sub>4</sub>-alkylthio, C<sub>2</sub>-C<sub>5</sub>-alkoxycarbonyl, aminocarbonyl, C<sub>3</sub>-C<sub>9</sub>-dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy, NR<sup>5</sup>R<sup>6</sup>, and bridged R<sup>1</sup>R<sup>2</sup>; wherein

R<sup>2</sup> is selected from the group consisting of hydrogen

and C<sub>1</sub>-C<sub>6</sub>-alkyl; and

R<sup>6</sup> is selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>6</sub>-alkyl;

D2  
cont  
R<sup>2</sup> is selected from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, trifluoromethyl and hydroxy and bridged R<sup>1</sup>R<sup>2</sup>;

C2  
wherein

bridged R<sup>1</sup>R<sup>2</sup> is where R<sup>1</sup>R<sup>2</sup> are adjacent and form a bridge which is selected from the group consisting of -(CH<sub>2</sub>)<sub>4</sub>-, (CH=CH)<sub>2</sub>- and -CH<sub>2</sub>O-CR<sup>7</sup>R<sup>8</sup>O-; wherein

R<sup>7</sup> is selected from the group consisting of hydrogen, and C<sub>1</sub>-C<sub>6</sub>-alkyl; and

R<sup>8</sup> is selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>6</sub>-alkyl;

R<sup>3</sup> is selected from the group consisting of hydrogen, halogen and C<sub>1</sub>-C<sub>6</sub>-alkyl;

R<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-alkenyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy and benzyloxy;

k is 0 or 1,

A is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>6</sub>-alkenylene which is substituted one to three-fold by C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy, fluorine, cyano, or phenyl,

C<sub>4</sub>-C<sub>6</sub>-alkadienylene,

a substituted C<sub>4</sub>-C<sub>6</sub>-alkadienylene which is substituted

once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl, fluorine, cyano, or phenyl,  
1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted  
by C<sub>1</sub>-C<sub>3</sub>-alkyl, fluorine, or cyano, and ethynylene;

D is selected from the group consisting of

C<sub>1</sub>-C<sub>10</sub>-alkylene,

a substituted C<sub>1</sub>-C<sub>10</sub>-alkylene which is substituted once or  
twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,

C<sub>2</sub>-C<sub>10</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>10</sub>-alkenylene which is substituted once  
or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,

a substituted C<sub>2</sub>-C<sub>10</sub>-alkenylene which is substituted once  
or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy, wherein the double bond is  
to E,


C<sub>3</sub>-C<sub>10</sub>-alkynylene,

a substituted C<sub>3</sub>-C<sub>10</sub>-alkynylene which is substituted once  
or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,

an isosterically replaced C<sub>1</sub> to C<sub>10</sub> group selected from  
the group consisting of C<sub>1</sub>-C<sub>10</sub>-alkylene, C<sub>2</sub>-C<sub>10</sub>-alkenylene and  
C<sub>3</sub>-C<sub>10</sub>-alkynylene, the isosterically replaced C<sub>1</sub> to C<sub>10</sub> group  
having methylene units and one to three of the methylene units  
are isosterically replaced by O, S, NR<sup>9</sup>, CO, SO or SO<sub>2</sub>; wherein

R<sup>9</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-  
C<sub>3</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-acyl and methanesulfonyl;

E is



wherein **n** and **p** are, independent of each other, 0, 1, 2, or 3 wherein  $n + p \leq 3$ ,

**R<sup>10</sup>** is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy, hydroxymethyl, carboxy and C<sub>2</sub>-C<sub>7</sub>-alkoxycarbonyl;

**R<sup>11</sup>** is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E;

**G** is selected from the group consisting of hydrogen, **G1**, **G2**, **G3**, **G4** and **G5**; wherein

**G1** is  $-(CH_2)_r-(CR^{13}R^{14})_s-R^{12}$

wherein

**r** is 0, 1 or 2, and

**s** is 0 or 1,

**R<sup>12</sup>** is selected from the group consisting of hydrogen,

C<sub>1</sub>-C<sub>6</sub>-alkyl,

C<sub>3</sub>-C<sub>6</sub>-alkenyl,

C<sub>3</sub>-C<sub>6</sub>-alkinyl,

C<sub>3</sub>-C<sub>8</sub>-cycloalkyl,

benzyl,

phenyl,

monocyclic aromatic five- and six-membered heterocycles which heterocycles contain one to three hetero-atoms selected



from the group consisting of N, S and O, which heterocycles are bound directly to or over a methylene group,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms are selected from N, S and O and the carbocyclic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring, and either directly or over a methylene group;

$R^{13}$  has the same meaning as  $R^{12}$ , but is selected independently thereof;

$R^{14}$  is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl,



monocyclic aromatic five- and six-membered heterocycles which contain one to three hetero-atoms selected from the group consisting of N, S and O and are bound either directly or over a methylene group,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and the aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or


over a methylene group, and

a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, which heterocycles contain one to three ring atoms are selected from N, S and O and the heterocyclic ring and aromatic ring being bonded with a bond which is over an aromatic or a hydrogenated ring and either directly or over a methylene group;

G2 is selected from the group consisting of



and



wherein  $\text{R}^{12}$  and  $\text{R}^{14}$  have the above meaning, and Q

is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of

saturated and unsaturated monocyclic, four- to eight-membered heterocycles,

saturated and unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N,


S and O,

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms;

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

G3 is  $-\text{SO}_2-(\text{CH}_2)_x-\text{R}^{12}$ ,

G4 is



wherein

$\text{Ar}^1$  is selected from the group consisting of phenyl, pyridyl and naphthyl; and

$\text{Ar}^2$  is selected from the group consisting of phenyl, pyridyl and naphthyl;

G5 is  $-\text{COR}^{15}$ ,

wherein


$\text{R}^{15}$  is selected from the group consisting of trifluoromethyl,  $\text{C}_1\text{-C}_6\text{-alkoxy}$ ,  $\text{C}_3\text{-C}_6\text{-alkenyloxy}$  and benzyloxy; and

C2  
D2  
Cont

wherein aromatic rings in  $R^1$ ,  $R^4$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $Q$ ,  $Ar^1$  and  $Ar^2$  are unsubstituted or substituted, the substituted rings in  $R^1$ ,  $R^4$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $Q$ ,  $Ar^1$  and  $Ar^2$  having one to three substituents which are independently selected from the group consisting of halogen, cyano,  $C_1$ - $C_6$ -alkyl, trifluoromethyl,  $C_2$ - $C_6$ -cycloalkyl, phenyl, benzyl, hydroxy,  $C_1$ - $C_6$ -alkoxy, and a substituted  $C_1$ - $C_6$ -alkoxy which is entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto,  $C_1$ - $C_6$ -alkylthio, carboxy,  $C_1$ - $C_6$ -alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono- $C_1$ - $C_6$ -alkylamino, and di- $(C_1$ - $C_6$ -alkyl)-amino, wherein two adjacent groups of an aromatic ring in the substituted  $C_1$ - $C_6$  alkoxy may form an additional ring over a methylenedioxy bridge,

wherein general formula (I) does not include (E)-3-(3-pyridyl)-N-[2-(1-benzylpiperidin-4-yl)ethyl]-2-propenamide.

64. (once amended) A method of inhibiting tumor cell growth in a human or animal body comprising administering to the human or animal body an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition includes a compound of general formula (I)



(I)

wherein:

D3  
cont

$R^1$  is selected from the group consisting of hydrogen, halogen, cyano,  $C_1-C_6$ -alkyl, trifluoromethyl,  $C_3-C_8$ -cycloalkyl,  $C_1-C_6$ -hydroxyalkyl, hydroxy,  $C_1-C_6$ -alkoxy, benzyloxy,  $C_2-C_4$ -alkanoyloxy,  $C_1-C_4$ -alkylthio,  $C_2-C_5$ -alkoxycarbonyl, aminocarbonyl,  $C_3-C_9$ -dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy,  $NR^5R^6$ , and bridged  $R^1R^2$ ; wherein

C3

$R^5$  is selected from the group consisting of hydrogen and  $C_1-C_6$ -alkyl; and

$R^6$  is selected from the group consisting of hydrogen and  $C_1-C_6$ -alkyl;

$R^2$  is selected from the group consisting of hydrogen, halogen,  $C_1-C_6$ -alkyl, trifluoromethyl and hydroxy and bridged  $R^1R^2$ ;

wherein

bridged  $R^1R^2$  is where  $R^1R^2$  are adjacent and form a bridge which is selected from the group consisting of  $-(CH_2)_4-$ ,  $(CH=CH)_2-$  and  $-CH_2O-CR^7R^8-O-$ ; wherein

$R^7$  is selected from the group consisting of hydrogen, and  $C_1-C_6$ -alkyl; and

$R^8$  is selected from the group consisting of hydrogen and  $C_1-C_6$ -alkyl;

$R^3$  is selected from the group consisting of hydrogen, halogen and  $C_1-C_6$ -alkyl;

$R^4$  is selected from the group consisting of hydrogen,  $C_1-C_6$ -alkyl,  $C_3-C_6$ -alkenyl, hydroxy,  $C_1-C_6$ -alkoxy and benzyloxy;

$k$  is 0 or 1,

*B3 cont*  
A is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>6</sub>-alkenylene which is substituted one to three-fold by C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy, fluorine, cyano, or phenyl,

C<sub>4</sub>-C<sub>6</sub>-alkadienylene,

a substituted C<sub>4</sub>-C<sub>6</sub>-alkadienylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl, fluorine, cyano, or phenyl, 1,3,5-hexatrienylene,

*C3*  
a substituted 1,3,5-hexatrienylene which is substituted by C<sub>1</sub>-C<sub>3</sub>-alkyl, fluorine, or cyano, and ethynylene;

D is selected from the group consisting of

C<sub>1</sub>-C<sub>10</sub>-alkylene,

a substituted C<sub>1</sub>-C<sub>10</sub>-alkylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,

C<sub>2</sub>-C<sub>10</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>10</sub>-alkenylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,


a substituted C<sub>2</sub>-C<sub>10</sub>-alkenylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy, wherein the double bond is to E,

C<sub>3</sub>-C<sub>10</sub>-alkinylene,

a substituted C<sub>3</sub>-C<sub>10</sub>-alkinylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,

an isosterically replaced C<sub>1</sub> to C<sub>10</sub> group selected from the group consisting of C<sub>1</sub>-C<sub>10</sub>-alkylene, C<sub>2</sub>-C<sub>10</sub>-alkenylene and C<sub>3</sub>-C<sub>10</sub>-alkinylene, the isosterically replaced C<sub>1</sub> to C<sub>10</sub> group having methylene units and one to three of the methylene units are isosterically replaced by O, S, NR<sup>9</sup>, CO, SO or SO<sub>2</sub>; wherein

R<sup>9</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-acyl and methanesulfonyl;



03

wherein  $n$  and  $p$  are, independent of each other, 0, 1, 2, or 3 wherein  $n + p \leq 3$ ,

R<sup>10</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy, hydroxymethyl, carboxy and C<sub>2</sub>-C<sub>7</sub>-alkoxycarbonyl;

R<sup>11</sup> is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E;

G is selected from the group consisting of hydrogen, G1, G2, G3, G4 and G5; wherein

G1 is  $-(CH_2)_r-(CR^{13}R^{14})_s-R^{12}$

wherein

$r$  is 0, 1 or 2, and

$s$  is 0 or 1,

R<sup>12</sup> is selected from the group consisting of

03  
cont

hydrogen,  
C<sub>1</sub>-C<sub>6</sub>-alkyl,  
C<sub>3</sub>-C<sub>6</sub>-alkenyl,  
C<sub>3</sub>-C<sub>6</sub>-alkinyl,  
C<sub>3</sub>-C<sub>6</sub>-cycloalkyl,  
benzyl,  
phenyl,

03

monocyclic aromatic five- and six-membered heterocycles which heterocycles contain one to three hetero-atoms selected from the group consisting of N, S and O, which heterocycles are bound directly to or over a methylene group,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms are selected from N, S and O and the carbocyclic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring, and either directly or over a methylene group;

R<sup>13</sup> has the same meaning as R<sup>12</sup>, but is selected independently thereof;

R<sup>14</sup> is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl,





monocyclic aromatic five- and six-membered heterocycles which contain one to three hetero-atoms selected from the group consisting of N, S and O and are bound either directly or over a methylene group,


an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and the aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, which heterocycles contain one to three ring atoms are selected from N, S and O and the heterocyclic ring and aromatic ring being bonded with a bond which is over an aromatic or a hydrogenated ring and either directly or over a methylene group;

G2 is selected from the group consisting of



and



83  
Cont

wherein  $R^{12}$  and  $R^{14}$  have the above meaning, and Q is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of

saturated and unsaturated monocyclic, four- to eight-membered heterocycles,

83


saturated and unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms;

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

G3 is  $-SO_2-(CH_2)_x-R^{12}$ ,

G4 is



wherein

$\text{Ar}^1$  is selected from the group consisting of phenyl, pyridyl and naphthyl; and

$\text{Ar}^2$  is selected from the group consisting of

phenyl, pyridyl and naphthyl;


*D3*  
*cont*  
G5 is -COR<sup>15</sup>,

wherein

*C3*  
R<sup>15</sup> is selected from the group consisting of trifluoromethyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>3</sub>-C<sub>6</sub>-alkenyloxy and benzyloxy; and

wherein aromatic rings in R<sup>1</sup>, R<sup>4</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, Q, Ar<sup>1</sup> and Ar<sup>2</sup> are unsubstituted or substituted, the substituted rings in R<sup>1</sup>, R<sup>4</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, Q, Ar<sup>1</sup> and Ar<sup>2</sup> having one to three substituents which are independently selected from the group consisting of halogen, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, trifluoromethyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, phenyl, benzyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, and a substituted C<sub>1</sub>-C<sub>6</sub>-alkoxy which is entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C<sub>1</sub>-C<sub>6</sub>-alkylthio, carboxy, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C<sub>1</sub>-C<sub>6</sub>-alkylamino, and di-(C<sub>1</sub>-C<sub>6</sub>-alkyl)-amino, wherein two adjacent groups of an aromatic ring in the substituted C<sub>1</sub>-C<sub>6</sub> alkoxy may form an additional ring over a methylenedioxy bridge.

65. (Once amended) A method of suppressing autoimmune disease in a human or animal body comprising administering to the human or animal body an effective amount of a pharmaceutical composition of, wherein the pharmaceutical composition includes a compound of general formula (I) or a pharmaceutically acceptable salt of formula (I)



03  
cont

wherein:

$R^1$  is selected from the group consisting of hydrogen, halogen, cyano,  $C_1$ - $C_6$ -alkyl, trifluoromethyl,  $C_3$ - $C_8$ -cycloalkyl,  $C_1$ - $C_4$ -hydroxyalkyl, hydroxy,  $C_1$ - $C_4$ -alkoxy, benzyloxy,  $C_2$ - $C_4$ -alkanoyloxy,  $C_1$ - $C_4$ -alkylthio,  $C_2$ - $C_5$ -alkoxycarbonyl, aminocarbonyl,  $C_3$ - $C_9$ -dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy,  $NR^5R^6$ , and bridged  $R^1R^2$ ; wherein

$R^5$  is selected from the group consisting of hydrogen and  $C_1$ - $C_6$ -alkyl; and

$R^6$  is selected from the group consisting of hydrogen and  $C_1$ - $C_6$ -alkyl;

$R^2$  is selected from the group consisting of hydrogen, halogen,  $C_1$ - $C_6$ -alkyl, trifluoromethyl and hydroxy and bridged  $R^1R^2$ ;

wherein

bridged  $R^1R^2$  is where  $R^1R^2$  are adjacent and form a bridge which is selected from the group consisting of  $-(CH_2)_4-$ ,  $(CH=CH)_2-$  and  $-CH_2O-CR^7R^8-O-$ ; wherein

$R^7$  is selected from the group consisting of hydrogen,

and C<sub>1</sub>-C<sub>6</sub>-alkyl; and

*03*  
*ant* **R<sup>8</sup>** is selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>6</sub>-alkyl;

**R<sup>3</sup>** is selected from the group consisting of hydrogen, halogen and C<sub>1</sub>-C<sub>6</sub>-alkyl;

**R<sup>4</sup>** is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-alkenyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy and benzyloxy;

*C<sup>3</sup>* **k** is 0 or 1,

**A** is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>6</sub>-alkenylene which is substituted one to three-fold by C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy, fluorine, cyano, or phenyl, C<sub>4</sub>-C<sub>6</sub>-alkadienylene,

a substituted C<sub>4</sub>-C<sub>6</sub>-alkadienylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl, fluorine, cyano, or phenyl, 1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted by C<sub>1</sub>-C<sub>3</sub>-alkyl, fluorine, or cyano, and ethynylene;

**D** is selected from the group consisting of

C<sub>1</sub>-C<sub>10</sub>-alkylene,

a substituted C<sub>1</sub>-C<sub>10</sub>-alkylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,

C<sub>2</sub>-C<sub>10</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>10</sub>-alkenylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,

a substituted C<sub>2</sub>-C<sub>10</sub>-alkenylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy, wherein the double bond is to E,

*Def Cont*


C<sub>3</sub>-C<sub>10</sub>-alkynylene,  
 a substituted C<sub>3</sub>-C<sub>10</sub>-alkynylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,

an isosterically replaced C<sub>1</sub> to C<sub>10</sub> group selected from the group consisting of C<sub>1</sub>-C<sub>10</sub>-alkylene, C<sub>2</sub>-C<sub>10</sub>-alkenylene and C<sub>3</sub>-C<sub>10</sub>-alkynylene, the isosterically replaced C<sub>1</sub> to C<sub>10</sub> group having methylene units and one to three of the methylene units are isosterically replaced by O, S, NR<sup>9</sup>, CO, SO or SO<sub>2</sub>; wherein

*C3*

R<sup>9</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-acyl and methanesulfonyl;

E is



wherein **n** and **p** are, independent of each other, 0, 1, 2, or 3 wherein **n + p ≤ 3**,

R<sup>10</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy, hydroxymethyl, carboxy and C<sub>2</sub>-C<sub>7</sub>-alkoxycarbonyl;

R<sup>11</sup> is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E;

G is selected from the group consisting of hydrogen, G1, G2, G3, G4 and G5; wherein

$G^1$  is  $-(CH_2)_r-(CR^{13}R^{14})_s-R^{12}$

wherein

*D3*  
*cont*  
 $r$  is 0, 1 or 2, and

$s$  is 0 or 1,

*C3*  
 $R^{12}$  is selected from the group consisting of

hydrogen,

$C_1$ - $C_6$ -alkyl,

$C_3$ - $C_6$ -alkenyl,

$C_3$ - $C_6$ -alkinyl,

$C_3$ - $C_8$ -cycloalkyl,

benzyl,

phenyl,

monocyclic aromatic five- and six-membered heterocycles which heterocycles contain one to three hetero-atoms selected from the group consisting of N, S and O, which heterocycles are bound directly to or over a methylene group,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms are selected from N, S and O and the carbocyclic ring and aromatic ring being bonded with a bond

which is either over an aromatic or a hydrogenated ring, and either directly or over a methylene group;

$R^{13}$  has the same meaning as  $R^{12}$ , but is selected independently thereof;


$R^{14}$  is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl,

monocyclic aromatic five- and six-membered heterocycles which contain one to three hetero-atoms selected from the group consisting of N, S and O and are bound either directly or over a methylene group,


an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and the aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, which heterocycles contain one to three ring atoms are selected from N, S and O and the heterocyclic ring and aromatic ring being bonded with a bond which is over an aromatic or a hydrogenated ring and either directly or over a methylene group;


$G2$  is selected from the group consisting of







and



wherein  $\text{R}^{12}$  and  $\text{R}^{14}$  have the above meaning, and Q is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of

saturated and unsaturated monocyclic, four- to eight-membered heterocycles,


saturated and unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S, and O,

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms;

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

G3 is  $\text{-SO}_2\text{-(CH}_2\text{)}_r\text{-R}^{12}$ ,

G4 is



wherein

*B3*  
*cont*  
 $\text{Ar}^1$  is selected from the group consisting of phenyl, pyridyl and naphthyl; and

$\text{Ar}^2$  is selected from the group consisting of phenyl, pyridyl and naphthyl;

*C3*  
 $\text{G5}$  is  $-\text{COR}^{15}$ ,


wherein

$\text{R}^{15}$  is selected from the group consisting of trifluoromethyl,  $\text{C}_1\text{-C}_6\text{-alkoxy}$ ,  $\text{C}_3\text{-C}_6\text{-alkenyloxy}$  and benzyloxy; and

wherein aromatic rings in  $\text{R}^1$ ,  $\text{R}^4$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{Q}$ ,  $\text{Ar}^1$  and  $\text{Ar}^2$  are unsubstituted or substituted, the substituted rings in  $\text{R}^1$ ,  $\text{R}^4$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{Q}$ ,  $\text{Ar}^1$  and  $\text{Ar}^2$  having one to three substituents which are independently selected from the group consisting of halogen, cyano,  $\text{C}_1\text{-C}_6\text{-alkyl}$ , trifluoromethyl,  $\text{C}_3\text{-C}_6\text{-cycloalkyl}$ , phenyl, benzyl, hydroxy,  $\text{C}_1\text{-C}_6\text{-alkoxy}$ ,  $\text{C}_1\text{-C}_6\text{-alkoxy}$ , and a  $\text{C}_1\text{-C}_6\text{-alkoxy}$  which is entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto,  $\text{C}_1\text{-C}_6\text{-alkylthio}$ , carboxy,  $\text{C}_1\text{-C}_6\text{-alkoxycarbonyl}$ , benzyloxycarbonyl, nitro, amino, mono- $\text{C}_1\text{-C}_6\text{-alkylamino}$ , and di- $(\text{C}_1\text{-C}_6\text{-alkyl})\text{-amino}$ , wherein two adjacent groups of an aromatic ring in the substituted  $\text{C}_1\text{-C}_6\text{-alkoxy}$  may form an additional ring over a methylenedioxy bridge.

Please add the following new claims.

68. A compound of formula (I) and pharmaceutically acceptable salts of formula (I)



(I)

wherein:

$R^1$  is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl and hydroxy,

$R^2$  and  $R^3$  are hydrogen,

$R^4$  is hydrogen or hydroxy,

$k$  is 0 or 1,

$A$  is selected from the group consisting of  $C_2$ - $C_4$ -alkenylene,

a substituted  $C_2$ - $C_4$ -alkenylene which is substituted with fluorine,

1,3-butadienylene, and

a substituted 1,3-butadienylene which is substituted with fluorine,

$D$  is selected from the group consisting of  $C_2$ - $C_6$ -alkylene,

a  $C_2$ - $C_6$ -alkenylene wherein the double bond is to  $E$ ,





a substituted  $C_2$ - $C_6$ -alkynylene which is substituted once

or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy, and


an isosterically replaced C<sub>2</sub>-C<sub>6</sub>-alkylene wherein a methylene unit of the alkenylene is isosterically replaced by O, NH, N(CH<sub>3</sub>) or CO, or an ethylene group of the alkenylene is isosterically replaced by NH-CO or CO-NH, or a propylene group of the alkenylene is isosterically replaced by NH-CO-O or O-CO-NH,

E is selected from pyrrolidine, piperidine, 1,2,5,6-tetrahydropyridine, hexahydroazepine, morpholine and hexahydro-1,4-oxazepine,

G is selected from the group consisting of hydrogen, tert-butoxycarbonyl, diphenylphosphinoyl,



and



wherein r is 0 or 1, and

s is 0 or 1,

R<sup>12</sup> is selected from the group consisting of hydrogen,

D3  
cont

hydrogen, methyl, benzyl, phenyl, indenyl, oxoindanyl, naphthyl, tetrahydronaphthyl, fluorenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, and dibenzocycloheptenyl, dihydrodibenzocycloheptenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, imidazothiazolyl, benzofuryl, benzothienyl, indolyl, oxoindolinyl, dioxoindolinyl, benzoxazolyl, oxobenzoxazolinyl, benzothiazolyl, oxobenzthiazolinyl, benzimidazolyl, oxobenzimidazolinyl, benzofurazanyl, benzotriazolyl, oxazolopyridyl, oxodihydrooxazolopyridyl, thiazolopyridyl, oxodihydrothiazolopyridyl, chromanyl, chromanonyl, benzopyranyl, chromonyl, quinolyl, isoquinolyl, oxodihydroquinolinyl, tetrahydroquinolyl, oxotetrahydroquinolinyl, benzodioxanyl, quinazolinyl, acridinyl, oxodihydroacridinyl, phenothiazinyl, dihydrodibenzoxepinyl, benzocycloheptathienyl, dihydrothienobenzothiepinyl, dihydrodibenzothiepinyl, oxodihydrodibenzothiepinyl, dihydrodibenzazepinyl, oxodihydrodibenzazepinyl, octahydrodibenzazepinyl, benzocycloheptapyridyl, oxobenzocycloheptapyridyl, and dihydrodibenzothiazepinyl,

C4

R<sup>13</sup> is selected from the group consisting of hydrogen, methyl, benzyl or and phenyl,

R<sup>14</sup> is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl, and


the group consisting of naphthyl, furyl, thienyl, pyridyl, benzofuryl, benzothienyl, indolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, chromanyl, quinolyl and tetrahydroquinolyl,

wherein Q is selected from the group consisting of pyrrolidine, piperidine, hexahydroazepine, morpholine, 2,5-

C4  
D3  
Cont

diazabicyclo[2.2.1]heptane, indoline, isoindoline, (1H)-  
dihydroquinoline, (1H)-tetrahydroquinoline, (2H)-  
tetrahydroisoquinoline, (1H)-tetrahydrobenzo[b]azepine, (1H)-  
tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine,  
(5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-  
tetrahydroacridanone, (5H)-dihyrodibenzazepine, (11H)-  
dihyrodibenzo[b,e]oxazepine and (11H)-  
dihyrodibenzo[b,e]thiazepine, wherein general formula (I)  
does not include (E)-3-(3-pyridyl)-N-[2-(1-benzylpiperidin-4-  
yl)ethyl]-2-propenamide.


69. A method for the production of compounds having general formula (I)



(I)

the method comprising:

reacting a carboxylic acids of formula (II)



(II)

with compounds of formula (III)

H-N-D-E-G (III)



wherein

*B3*  
*cont*  
*C4*  
 $R^1$  is selected from the group consisting of hydrogen, halogen, cyano,  $C_1-C_6$ -alkyl, trifluoromethyl,  $C_3-C_8$ -cycloalkyl,  $C_1-C_6$ -hydroxyalkyl, hydroxy,  $C_1-C_6$ -alkoxy, benzyloxy,  $C_2-C_4$ -alkanoyloxy,  $C_1-C_6$ -alkylthio,  $C_2-C_6$ -alkoxycarbonyl, aminocarbonyl,  $C_3-C_9$ -dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy,  $NR^5R^6$ , and bridged  $R^1R^2$  wherein

$R^5$  is selected from the group consisting of hydrogen and  $C_1-C_6$ -alkyl, and

$R^6$  is selected from the group consisting of hydrogen and  $C_1-C_6$ -alkyl,

$R^2$  is selected from the group consisting of hydrogen, halogen,  $C_1-C_6$ -alkyl, trifluoromethyl and hydroxy and bridged  $R^1R^2$

wherein

bridged  $R^1R^2$  is where  $R^1R^2$  are adjacent and form a bridge which is selected from the group consisting of  $-(CH_2)_4-$ ,  $(CH=CH)_2-$  and  $-CH_2O-CR^7R^8-O-$ , wherein

$R^7$  is selected from the group consisting of hydrogen, and  $C_1-C_6$ -alkyl and

$R^8$  is selected from the group consisting of hydrogen and  $C_1-C_6$ -alkyl,

$R^3$  is selected from the group consisting of hydrogen, halogen and  $C_1-C_6$ -alkyl,



$R^4$  is selected from the group consisting of hydrogen,  $C_1$ -alkyl,  $C_3$ - $C_6$ -alkenyl, hydroxy,  $C_1$ - $C_6$ -alkoxy and benzyloxy,

$k$  is 0 or 1,

*D<sup>3</sup> cont*  
 $A$  is selected from the group consisting of  $C_2$ - $C_6$ -alkenylene,

a substituted  $C_2$ - $C_6$ -alkenylene which is substituted one to three-fold by  $C_1$ - $C_3$ -alkyl, hydroxy, fluorine, cyano, or phenyl,  $C_4$ - $C_6$ -alkadienylene,

*C<sup>4</sup>*  
a substituted  $C_4$ - $C_6$ -alkadienylene which is substituted once or twice by  $C_1$ - $C_3$ -alkyl, fluorine, cyano, or phenyl, 1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted by  $C_1$ - $C_3$ -alkyl, fluorine, or cyano, and ethynylene,

$D$  is selected from the group consisting of

$C_1$ - $C_{10}$ -alkylene,

a substituted 1,3,5-hexatrienylene which is substituted once or twice by  $C_1$ - $C_3$ -alkyl or hydroxy,  $C_2$ - $C_{10}$ -alkenylene,

a substituted  $C_2$ - $C_{10}$ -alkenylene which is substituted once or twice by  $C_1$ - $C_3$ -alkyl or hydroxy,


$C_3$ - $C_{10}$ -alkynylene,

a substituted  $C_3$ - $C_{10}$ -alkynylene which is substituted once or twice by  $C_1$ - $C_3$ -alkyl or hydroxy,

an isosterically replaced  $C_1$  to  $C_{10}$  group selected from the group consisting of  $C_1$ - $C_{10}$ -alkylene,  $C_2$ - $C_{10}$ -alkenylene and  $C_3$ - $C_{10}$ -alkynylene, the isosterically replaced  $C_1$  to  $C_{10}$  group having methylene units and one to three of the methylene units are isosterically replaced by O, S,  $NR^9$ , CO, SO or  $SO_2$ , wherein

$R^9$  is selected from selected from the group consisting of hydrogen,  $C_1$ - $C_3$ -alkyl,  $C_2$ - $C_6$ -acyl and methanesulfonyl,

E is



wherein  $n$  and  $p$  are, independent of each other, 0, 1, or 2, wherein  $n + p = 2$ ,

C4  
 $R^{10}$  is selected from the group consisting of hydrogen,  $C_1$ - $C_3$ -alkyl, hydroxy, hydroxymethyl, carboxy and  $C_2$ - $C_1$ -alkoxycarbonyl,

$R^{11}$  is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E,

G is selected from the group consisting of hydrogen,  $G_1$ ,  $G_2$ ,  $G_3$ ,  $G_4$  and  $G_5$ , wherein

G1 is  $-(CH_2)_r-(CR^{13}R^{14})_s-R^{12}$   
wherein

r is 0, 1 or 2, and

s is 0 or 1,

$R^{12}$  is selected from the group consisting of hydrogen,  
 $C_1$ - $C_6$ -alkyl,  
 $C_3$ - $C_6$ -alkenyl,  
 $C_3$ - $C_6$ -alkinyl,

C<sub>3</sub>-C<sub>8</sub>-cycloalkyl,

benzyl,

phenyl,

D3  
cont  
monocyclic aromatic five- and six-membered heterocycles which heterocycles contain one to three hetero-atoms selected from the group consisting of N, S and O, the N, S and O being either bound directly to or over a methylene group,

C4  
an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carboxylic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms are selected from N, S and O and the carbocyclic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring, and either directly or over a methylene group,

R<sup>13</sup> has the same meaning as R<sup>12</sup>, but is selected independently thereof,

R<sup>14</sup> is selected from the group consisting of hydrogen, hydroxy,

methyl,

benzyl,

phenyl,



monocyclic aromatic five- and six-membered heterocycles which contain one to three hetero-atoms selected from the group consisting of N, S and O and are bound either directly or over a methylene group,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms


and at least one aromatic ring and the carbocyclic ring and the aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

<sup>D3</sup>  
cont a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, which heterocycles contain one to three ring atoms are selected from N, S and O and the heterocyclic ring and aromatic ring being bonded with a bond which is over an aromatic or a hydrogenated ring and either directly or over a methylene group,

<sup>C4</sup> G2 is selected from the group consisting of



and



wherein R<sup>12</sup> and R<sup>14</sup> have the above meaning, and Q


is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of

saturated and unsaturated monocyclic, four- to eight-membered heterocycles,  
and

saturated and unsaturated bi- or tricyclic, annellated or bridged heterocycles with 8 to 16 ring atoms,

G3 is  $-\text{SO}_2-(\text{CH}_2)_r-\text{R}^{12}$ ,

G4 is



wherein

$\text{Ar}^1$  is selected from the group consisting of phenyl, pyridyl and naphthyl and

$\text{Ar}^2$  is selected from the group consisting of phenyl, pyridyl and naphthyl,


G5 is  $-\text{COR}^{15}$ ,

wherein

$\text{R}^{15}$  is selected from the group consisting of trifluoromethyl,  $\text{C}_1\text{-C}_6\text{-alkoxy}$ ,  $\text{C}_3\text{-C}_6\text{-alkenyloxy}$  and benzyloxy, and

wherein aromatic rings in  $\text{R}^1$ ,  $\text{R}^4$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ , Q,  $\text{Ar}^1$  and  $\text{Ar}^2$  are unsubstituted or substituted, the substituted rings in  $\text{R}^1$ ,  $\text{R}^4$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ , Q,  $\text{Ar}^1$  and  $\text{Ar}^2$  having one to three substituents which are independently selected from the group consisting of halogen, cyano,  $\text{C}_1\text{-C}_6\text{-alkyl}$ , trifluoromethyl,  $\text{C}_3\text{-C}_8\text{-cycloalkyl}$ , phenyl, benzyl, hydroxy, and  $\text{C}_1\text{-C}_6\text{-alkoxy}$ .

70. A compound of formula (I) and pharmaceutically acceptable acid salts of formula I



wherein:

R<sup>1</sup> = H or F

k is 0 or 1,

A is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub>-alkenylene,

a substituted C<sub>2</sub>-C<sub>6</sub>-alkenylene which is substituted one to three-fold by C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy, fluorine, cyano, or phenyl, C<sub>4</sub>-C<sub>6</sub>-alkenylene,

a substituted C<sub>4</sub>-C<sub>6</sub>-alkadienylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl, fluorine, cyano, or phenyl, 1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted by C<sub>1</sub>-C<sub>3</sub>-alkyl, fluorine, or cyano, and ethynylene;

R<sup>2</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-alkenyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy and benzyloxy;

D is selected from the group consisting of C<sub>1</sub>-C<sub>10</sub>-alkylene,

a substituted 1,3,5-hexatrienylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,

**C<sub>2</sub>-C<sub>10</sub>-alkenylene,**

**a substituted C<sub>2</sub>-C<sub>10</sub>-alkenylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,**


**C<sub>3</sub>-C<sub>10</sub>-alkynylene,**

**a substituted C<sub>3</sub>-C<sub>10</sub>-alkynylene which is substituted once or twice by C<sub>1</sub>-C<sub>3</sub>-alkyl or hydroxy,**

**an isotERICALLY replaced C<sub>1</sub> to C<sub>10</sub> group selected from the group consisting of C<sub>1</sub>-C<sub>10</sub>-alkylene, C<sub>2</sub>-C<sub>10</sub>-alkenylene and C<sub>3</sub>-C<sub>10</sub>-alkynylene, the isotERICALLY replaced C<sub>1</sub> to C<sub>10</sub> group having methylene units and one to three of the methylene units being isotERICALLY replaced by O, S, NR<sup>3</sup>, CO SO or SO<sub>2</sub>;**

**R<sup>3</sup> is selected from selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-acyl and methanesulfonyl;**

**E is**



**G is selected from the group consisting of**

**-(CH<sub>2</sub>)<sub>x</sub>-(CR<sup>4</sup>R<sup>6</sup>)<sub>n</sub>R<sup>5</sup>,**

**-C-(CH<sub>2</sub>)<sub>x</sub>-(CR<sup>4</sup>R)<sub>n</sub>R<sup>6</sup>,**

**|**

**O**

**-C-(CH<sub>2</sub>)<sub>x</sub>-NR<sup>4</sup>R<sup>6</sup>,**

**|**

**O**

**-SO<sub>2</sub>(CH<sub>2</sub>)<sub>x</sub>R<sup>4</sup>,**



*03*  
*cont*  
  
*C4*  
r=0, 1 or 2,

s=0 or 1,

R<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, benzyl phenyl, and substituted phenyl which substituted phenyl is substituted with one to three substituents selected from the group consisting of halogen, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, trifluoromethyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, phenyl, benzyl, hydroxy, and C<sub>1</sub>-C<sub>6</sub>-alkoxy;

R<sup>5</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, benzyl phenyl, and substituted phenyl which substituted phenyl is substituted with one to three substituents selected from the group consisting of halogen, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, trifluoromethyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, phenyl, benzyl, hydroxy, and C<sub>1</sub>-C<sub>6</sub>-alkoxy;

R<sup>6</sup> is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, and phenyl;


R<sup>7</sup> is selected from trifluoromethyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>3</sub>-C<sub>6</sub>-alkenyloxy and benzyloxy;

R<sup>8</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>3</sub>-alkyl, hydroxy, hydroxymethyl, carboxy and C<sub>2</sub>-C<sub>7</sub>-alkoxycarbonyl;

and wherein general formula (I) does not include (E)-3-(3-pyridyl)-N-[2-(1-benzylpiperidin-4-yl)ethyl]-2-propenamide..



71. A compound of formula (I) and pharmaceutically acceptable salts of formula (I)



wherein:

R¹ is selected from the group consisting of hydrogen, fluorine, chlorine, methoxy, methyl, and hydroxy;

R² and R³ are hydrogen;

R⁴ is hydrogen, methyl or hydroxy;

k is 0 or 1;

A is selected from the group consisting of C₂-C₄-alkenylene,


a substituted C₂-C₄-alkenylene which is substituted with fluorine, cyano, hydroxy and methyl,

1,3-butadienylene, and



a substituted 1,3-butadienylene which is substituted with fluorine;






DEG when together form the structure selected from the group consisting of

B<sup>3</sup>  
cont









C4

















D<sup>3</sup>  
cont

C4










O3  
cont




C4

B<sup>3</sup>  
cont


C<sup>4</sup>



D<sup>3</sup>  
cont




C4









B<sup>3</sup>  
cont












C4








D<sup>3</sup>  
cont

C4





B3  
cont


C4




D3  
cont






C4



D<sup>3</sup>  
cont







C4







D<sup>3</sup>  
Cont

C4




D3  
cont

C4








D3  
cont








C4







03  
cont


C4







D<sup>3</sup>  
cont



C4








D3  
cont




D<sup>3</sup>  
cont





C4








D<sup>3</sup>  
cont








C4



B<sup>3</sup>  
cont









D<sup>3</sup>  
cont










D<sup>3</sup>  
cont

C4








O<sup>3</sup>  
cont

C4









B<sup>3</sup>  
cont

C4








D<sup>3</sup>  
cont

C4









D3  
cont

C4








D3  
cont

C4








P<sup>3</sup>  
cont

C4



D<sup>3</sup>  
cont






C4






B3  
cont




C4



103  
cont








C4



D<sup>3</sup>  
cont

C4



B3  
out

72. A method of inhibiting tumor cell growth according to claim 64, wherein the composition is administered by a method selected from the group consisting of subcutaneously, intramuscularly, intravenously, intracutaneous, orally, sublingually, transdermally, topically and combinations thereof.

73. A method of inhibiting tumor cell growth according to claim 64, wherein the composition is administered in combination with compounds selected from the group consisting of cytostatic agents, DNA intercalating substances, topoisomerase inhibitors, spindle poisons, hormonally active agents, and mixtures thereof.

C4

74. A method of inhibiting tumor cell growth according to claim 64, wherein cytostatic agents are selected from the group consisting of

L-asparaginase, bleomycin, hydroxyurea, P-glycoprotein, MRP, glutathione-S-transferase, metallothionein, and mixtures thereof;

antimetabolites selected from the group consisting of cytarabine, 5-fluorouracil, 6-mercaptopurine, methotrexate, and mixtures thereof;

alkylating agents selected from the group consisting of busulfan, carmustine, cisplatin, caroplatin, cyclophosphamide, dacarbazine, melphalan, thiotepea, and mixtures thereof;

DNA intercalating substances and topoisomerases selected from the group consisting of actinomycin D, daunorubicin, doxorubicin, mitomycin D, mitoxantrone, etoposide, topotecan irinotecan, and mixtures thereof;

spindle poisons selected from the group consisting of vincristine, navelbin, taxol, taxoter, and mixtures thereof; and

hormonally active agents selected from the group consisting of tamoxifen, flutimide, formestane, goserelin, and mixtures thereof.


D3  
cont

75. A method of inhibiting tumor cell growth according to claim 64, wherein the method is effective for inhibiting tumors selected from the group consisting of gynecological tumors, ovarian carcinomas, testicle tumors, esophagus carcinomas, stomach cancer, rectal carcinomas, pancreas carcinomas, thyroid cancer, adrenal tumors, leukemia, lymphomas, Hodgkin's disease, CNS tumors, soft-tissue sarcomas, bone sarcomas, benign and malignant mesotheliomas, intestine tumors, liver tumors, breast tumors, bronchial and lung carcinomas, melanomas, benign papillomatosis tumors, and combinations thereof.


C4

76. A method of inhibiting tumor cell growth according to claim 64, wherein the pharmaceutical composition is combined with a compound selected from the group consisting of pharmaceutically acceptable carriers, adjuvants, additives, and mixtures thereof.




77. A method of inhibiting tumor cell growth according to claim 64, wherein DEG is selected from the group consisting of




D<sup>3</sup>  
cont





C4









D<sup>3</sup>  
cont



C4











O<sup>3</sup>  
cont



C4







D<sup>3</sup>  
cont





C4

D<sup>3</sup>  
cont






C4


D<sup>3</sup>  
cont




C4





P<sup>3</sup>  
cont






C4






B<sup>3</sup>  
cont









C<sup>4</sup>



D3  
cont








C4





$D^3$   
cont


c4



P<sup>3</sup>  
cont







c4






9<sup>3</sup>  
cont




C4







103  
cont




C4











D<sup>3</sup>  
cont







C4




P3  
cont





C4





D<sup>3</sup>  
cont





C4



D3  
cont








C4










D<sup>3</sup>  
cont

C4








D<sup>3</sup>  
cont

C4








O<sup>3</sup>  
cont

C4









O<sup>3</sup>  
cont

C4








Q3  
cont

C4








D<sup>3</sup>  
cont

C<sup>4</sup>









P<sup>3</sup>  
cont

C4



D<sup>3</sup>  
cont






C4






P3  
cont

C4








03  
cont






C4





D<sup>3</sup>  
cont

C4









P<sup>3</sup>  
cont






C4



D<sup>3</sup>  
cont








c4



O<sup>3</sup>  
cont

C4



78. A method of suppressing autoimmune disease according to claim 65, wherein the composition is administered by a method selected from the group consisting of subcutaneously, intramuscularly, intravenously, intracutaneous, orally, sublingually, transdermally, topically, and combinations thereof.

79. A method of suppressing autoimmune disease according to claim 65, wherein the composition is administered in combination with other immunosuppressive agents.

C4  
80. A method of suppressing autoimmune disease according to claim 65, wherein the other immunosuppressive agents are selected from the group consisting of cyclosporin A, tacrolimus, rapamycin, and mixtures thereof;

antimetabolites selected from the group consisting of methotrexate, azothiaprime, and mixtures thereof; and glucocorticoids.

81. A method of suppressing autoimmune disease according to claim 65, wherein the pharmaceutical composition is combined with a compound selected from the group consisting of pharmaceutically acceptable carriers, adjuvants, additives, and mixtures thereof.




82. A method of suppressing autoimmune disease according to claim 65, wherein DEG is selected from the group consisting of

push  
B4








04  
cont

C4









94  
Cont









C4



O4  
cont

C4









DY  
cont

C4


B4  
cont






C4




04  
cont




C4





04  
cont






C4



OL  
cont












C4










94  
cont




CH







94  
cont

C4















04  
cont

C4




B4  
cont

C4








D9  
cont



C4

B4  
cont






C4








94  
cont

C4







OK  
cont

C4








P4  
cont

C4








04  
cont

C4








94  
cont

C4








04  
cont

C4









B<sup>4</sup>  
cont

C4



D4  
cont






C4










D4  
cont

C4









94  
cont

C4








94  
cont

C4









04  
cont

C4








B4  
cont

C4








04  
cont

C4








94  
cont

C4



94  
cont





C4





94  
cont

C4



D4  
cont

